相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab
Jacopo Giuliani et al.
ANTICANCER RESEARCH (2019)
Biosimilars for breast cancer
Bruna Migliavacca Zucchetti et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis
Hans-Peter Tony et al.
ARTHRITIS CARE & RESEARCH (2019)
Infusion Related Hypersensitivity Reactions with Bio-similar Anti CD-20 Monoclonal Antibody Rituximab in Indian Patients: A Retrospective Study
Gaurav Prakash et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2018)
Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study
Neh Nupur et al.
MABS (2018)
Infusion Related Hypersensitivity Reactions with Bio-similar Anti CD-20 Monoclonal Antibody Rituximab in Indian Patients: A Retrospective Study
Gaurav Prakash et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2018)
Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial
Won Park et al.
MABS (2018)
Extension Study of PF-05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis
Stanley B. Cohen et al.
ARTHRITIS CARE & RESEARCH (2018)
Past, Present, and Future of Rituximab-The world's First Oncology Monoclonal Antibody Therapy
Timothy M. Pierpont et al.
FRONTIERS IN ONCOLOGY (2018)
Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis
Manoela Manova et al.
FRONTIERS IN PHARMACOLOGY (2018)
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial
Michinori Ogura et al.
LANCET HAEMATOLOGY (2018)
Safety and Efficacy of an Anti-CD20 Monoclonal Antibody (Reditux™) In Indian Patients with Seropositive Rheumatoid Arthritis
Arun Hegde et al.
INDIAN JOURNAL OF RHEUMATOLOGY (2018)
Production costs and potential prices for biosimilars of human insulin and insulin analogues
Dzintars Gotham et al.
BMJ GLOBAL HEALTH (2018)
A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Long-term outcome of diffuse large B-cell lymphoma: Impact of biosimilar rituximab and radiation
P. Ganesan et al.
INDIAN JOURNAL OF CANCER (2017)
Scientific Evidence and Financial Obligations to Ensure Access to Biosimilars for Cancer Treatment
Howard Bauchner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials
Qian Shi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The process defines the product: what really matters in biosimilar design and production?
Arnold G. Vulto et al.
RHEUMATOLOGY (2017)
Long-term outcome of diffuse large B-cell lymphoma: Impact of biosimilar rituximab and radiation
P. Ganesan et al.
INDIAN JOURNAL OF CANCER (2017)
Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study
Wojciech Jurczak et al.
LANCET HAEMATOLOGY (2017)
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial
Won Seog Kim et al.
LANCET HAEMATOLOGY (2017)
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Gilles Salles et al.
ADVANCES IN THERAPY (2017)
A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial
Dae Hyun Yoo et al.
BIODRUGS (2017)
Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis
Won Park et al.
BIODRUGS (2017)
ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe
N. Cherny et al.
ANNALS OF ONCOLOGY (2016)
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Dreyling et al.
ANNALS OF ONCOLOGY (2016)
COMPARISON OF EFFICACY AND SAFETY OF RITUXIMAB BIOSIMILAR, BCD-020, AND INNOVATOR RITUXIMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS REFRACTORY TO TNFA INHIBITORS
A. Eremeeva et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab
Hector A. Cuello et al.
BIODRUGS (2016)
Comparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a proposed rituximab biosimilar, and rituximab
Jason H. Williams et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis
Stanley Cohen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma
Vikram Gota et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
A clinician's guide to biosimilars in oncology
Hope S. Rugo et al.
CANCER TREATMENT REVIEWS (2016)
Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux™) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs
Manjeet Bhati et al.
CLINICAL RHEUMATOLOGY (2016)
SpeB proteolysis with imaged capillary isoelectric focusing for the characterization of domain-specific charge heterogeneities of reference and biosimilar Rituximab
Zichuan Zhang et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2016)
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial
Mathias Rummel et al.
LANCET ONCOLOGY (2016)
Safety and efficacy of biosimilars in oncology
Huub Schellekens et al.
LANCET ONCOLOGY (2016)
Development of biosimilars
Ahmad AL-Sabbagh et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2016)
What do oncologists need to know about biosimilar products?
Linda K. S. Leung et al.
CHINESE JOURNAL OF CANCER (2016)
Biosimilars advancements: Moving on to the future
Lilian Rumi Tsuruta et al.
BIOTECHNOLOGY PROGRESS (2015)
Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies
Thomas R. W. Tipton et al.
BLOOD (2015)
Efficacy and safety of a biosimilar rituximab in biologic na⟨ve patients with active rheumatoid arthritis
Kuttipurath Kandi Roshique et al.
CLINICAL RHEUMATOLOGY (2015)
Key considerations in the preclinical development of biosimilars
Lynne A. Bui et al.
DRUG DISCOVERY TODAY (2015)
A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas
Pierre Feugier
FUTURE ONCOLOGY (2015)
Biosimilars in rheumatology: current perspectives and lessons learnt
Thomas Doerner et al.
NATURE REVIEWS RHEUMATOLOGY (2015)
Clinical trial development for biosimilars
Rieke Alten et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2015)
Rituximab: modes of action, remaining dispute and future perspective
Abdulmunem Abulayha et al.
FUTURE ONCOLOGY (2014)
PHYSICOCHEMICAL PROPERTIES OF RITUXIMAB
Luis F. Flores-Ortiz et al.
JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES (2014)
Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013
Antonio da Silva et al.
LEUKEMIA & LYMPHOMA (2014)
Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280586 and Rituximab (MabThera®)
Anne M. Ryan et al.
TOXICOLOGIC PATHOLOGY (2014)
Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey
William H. Baer et al.
PHARMACEUTICALS (2014)
Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab
Jan Visser et al.
BIODRUGS (2013)
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma
Emmanuel Bachy et al.
HAEMATOLOGICA (2013)
R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi
Massimo Federico et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis
Partha Sarathi Roy et al.
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY (2013)
Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars
Steven A. Berkowitz et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
The economic pressures for biosimilar drug use in cancer medicine
Paul Cornes
TARGETED ONCOLOGY (2012)
RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group
Verena I. Gaidzik et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
E. D. Saad et al.
ANNALS OF ONCOLOGY (2010)
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Bertrand Coiffier et al.
BLOOD (2010)
Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
Tadeusz Robak et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Issues in Using Progression-Free Survival When Evaluating Oncology Products
Thomas R. Fleming et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
Gilles Salles et al.
BLOOD (2008)
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL:: a prospective randomized HOVON trial
Edo Vellenga et al.
BLOOD (2008)
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
Robert Marcus et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma:: An East German Study Group hematology and oncology study
Michael Herold et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis
Ulrich J. M. Mey et al.
LEUKEMIA & LYMPHOMA (2006)
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
Marinus H. J. van Oers et al.
BLOOD (2006)
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
Thomas M. Habermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2006)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
W Hiddemann et al.
BLOOD (2005)
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte
P Feugier et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
R Marcus et al.
BLOOD (2005)
Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study
M Jermann et al.
ANNALS OF ONCOLOGY (2004)
Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy:: 9-year follow-up
MS Czuczman et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
From the bench to the bedside: ways to improve rituximab efficacy
G Cartron et al.
BLOOD (2004)
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
T Kewalramani et al.
BLOOD (2004)
End points and United States food and drug administration approval of oncology drugs
JR Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
分享论文
